Copyright: ©Author(s) 2026.
World J Clin Cases. Sep 6, 2026; 14(25): 124208
Published online Sep 6, 2026. doi: 10.12998/wjcc.124208
Published online Sep 6, 2026. doi: 10.12998/wjcc.124208
Table 1 Laboratory examinations during the patient’s disease course
| Liver function test | Reference range/Unit | August 31, 2025 | September 13, 2025 | December 14, 2025 |
| Total bilirubin | < 21.0 μmol/L | 7.00 | 9.30 | 7.03 |
| Direct bilirubin | ≤ 5.0 μmol/L | 4.54 | 5.60 | 4.13 |
| Alkaline phosphatase | 35-104 U/L | 220 | 212 | 120 |
| Alanine aminotransferase | < 35 U/L | 22.9 | 15.60 | 31.60 |
| Aspartate aminotransferase | < 35 U/L | 28.50 | 21.00 | 18.30 |
| Albumin | 35.0-52.0 g/L | 37.00 | 37.10 | 40.70 |
| Protein | 64-83 g/L | 84.60 | 70.20 | 71.20 |
| Complete blood count | Reference range/unit | September 13, 2025 | January 4, 2026 | March 18, 2026 |
| Hematocrit | 37%-47% | 24.3 | 35.4 | 34.7 |
| Nucleated red blood cells | 0-0.6/100 WBC | 0.2 | 0.1 | 0.1 |
| Red cell distribution width | 12.1%-16.2% | 18.2 | 20.2 | 15.8 |
| Mean platelet volume | 7.4-11.4 fL | 8.6 | 8.7 | 9.1 |
| Basophils | 0-0.1 × 103/μL | 0.0 | 0.0 | 0.0 |
| Eosinophils | 0-0.5 × 103/μL | 0.1 | 0.0 | 0.0 |
| Hemoglobin | 12.5-16.3 g/dL | 7.6 | 11.3 | 11.6 |
| Lymphocytes | 1-3.2 × 103/μL | 0.6 | 2.00 | 1.0 |
| Mean corpuscular hemoglobin | 23.8-33.4 pg | 24.6 | 24.6 | 29.2 |
| Mean corpuscular hemoglobin concentration | 32.5-36.3 g/dL | 31.3 | 31.8 | 33.5 |
| Mean corpuscular volume | 73.0-96.2 fL | 78.4 | 77.3 | 87.2 |
| Monocytes | 0.3-1.10 × 103/μL | 0.4 | 0.3 | 0.1 |
| Neutrophils | 1.70-7.60 × 103/μL | 2.00 | 4.80 | 3.9 |
| Platelet count | 150-410 × 103/μL | 138 | 110 | 101 |
| Red cell count | 4.06-5.63 × 103/μL | 3.11 | 4.58 | 3.97 |
| White cell count | 3.6-10.2 × 103/μL | 3.1 | 7.2 | 5.1 |
| Additional hematological tests. Absolute reticulocyte count (August 31, 2025). Absolute reticulocyte count (December 14, 2025) | 39-57 × 109/L; 39-57 × 109/L | 97; 84 | ||
| Prothrombin time | 11.7-15.3 seconds | 14.5 | ||
| International normalized ratio | 0.80-1.20 | 1.08 | ||
| Activated partial thromboplastin time | 28.6-40.0 seconds | 37.8 | ||
| Other laboratory tests | Reference range | Result | ||
| Procalcitonin | < 0.05 mg/mL | 0.17-0.52 | ||
| Ferritin | 30-250 ng/mL | 425 | ||
| D-dimer | 0.27-0.60 µg/mL | 2.05 | ||
| Angiotensin-converting enzyme | 20-70 U/L | 75.7 | ||
| Leishmania screening | Negative | Negative | ||
| Viral serology | Negative | Negative | ||
| Malarial antigen (Plasmodium falciparum) | Negative | Negative | ||
| Parvovirus B19 IgG and IgM | Negative | IgG positive: 29.4 IU/mL; IgM negative | ||
| QuantiFERON-TB gold test | Negative | Negative | ||
- Citation: Almasaabi M, Masood S, Elsayed G. Concurrent sarcoidosis and hemophagocytic lymphohistiocytosis: A case report. World J Clin Cases 2026; 14(25): 124208
- URL: https://www.wjgnet.com/2307-8960/full/v14/i25/124208.htm
- DOI: https://dx.doi.org/10.12998/wjcc.124208